Chronic pain in sickle cell disease: a role for lysophosphatidic acid
- 1 April 2026
- journal article
- Published by American Society of Hematology in Blood
- Vol. 148 (5) , 623-633
Abstract
Sickle cell disease (SCD) is a hereditary hemoglobinopathy characterized by persistent pain. The mechanisms underlying pain in SCD are poorly understood and opioids remain the primary treatment, despite their severe side effects. Here we investigated the contribution of lysophosphatidic acid (LPA), an endogenous pronociceptive lipid mediator, to chronic pain in SCD using humanized transgenic homozygous Berkeley mice that express >99% human sickle hemoglobin (HbSS mice) and control HbAA mice that express normal human hemoglobin A. Hyperalgesia in HbSS mice was associated with an increase in both plasma level of LPA and expression of LPAR1 mRNA in L1-L5 dorsal root ganglion (DRG). Blocking LPA synthesis with BI-2545 or blocking LPA1 receptor (LPA1R) function with siRNA or the LPA1R antagonist, AM966, reversed mechanical and heat hyperalgesia in HbSS mice. LPA also produced acute mechanical and heat hyperalgesia in HbAA mice, which resulted from the sensitization of C-fiber nociceptors. In HbSS mice, hyperalgesia was associated with sensitization of nociceptive DRG neurons. Nociceptors from hyperalgesic HbSS mice had lower rheobase, more positive resting membrane potential and higher frequency of action potential. Although no changes were found in the values of inward currents in nociceptors of HbSS mice compared to HbAA mice, outward-inactivating and non-inactivating currents were reduced, indicating the importance of potassium channels to sensitization in SCD. All these parameters were normalized by pretreatment of HbSS mice with LPA1R siRNA. Our results suggest that LPA signaling may be a promising target for treating pain in SCD.Keywords
This publication has 80 references indexed in Scilit:
- Comparative Analysis of Lysophosphatidic Acid Levels in Fibromyalgia and Other Painful Conditions in Female PatientsEuropean journal of pain, 2025
- Red blood cell pyruvate kinase properties in Townes and Berkeley sickle cell disease mouse models – Of mice and menBlood Cells, Molecules, and Diseases, 2025
- Different Profiles of the Triad of Lysophosphatidylcholine, Lysophosphatidic Acid, and Autotaxin in Patients with Neuropathic Pain Diseases: a Preliminary Observational StudyPain and Therapy, 2022
- Targeting TRPV1 activity via high‐dose capsaicin in patients with sickle cell diseaseeJHaem, 2022
- Pain-like behavior in the collagen antibody-induced arthritis model is regulated by lysophosphatidic acid and activation of satellite glia cellsBrain, Behavior, and Immunity, 2022
- Inhibition of lysophosphatidic acid receptor 1 attenuates neuroinflammation via PGE2/EP2/NOX2 signalling and improves the outcome of intracerebral haemorrhage in miceBrain, Behavior, and Immunity, 2021
- Quantification of pain in sickle mice using facial expressions and body measurementsBlood Cells, Molecules, and Diseases, 2016
- Patients with sickle cell disease have increased sensitivity to cold and heatAmerican Journal of Hematology, 2012
- Effects of lysophosphatidic acid on sodium currents in rat dorsal root ganglion neuronsBrain Research, 2005
- Quantitative assessment of tactile allodynia in the rat pawJournal of Neuroscience Methods, 1994